Menu Search
Equities

Co-Diagnostics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
C97:STU

Co-Diagnostics Inc

Actions
  • Price (EUR)5.61
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-71.23%
  • Beta1.3238
Data delayed at least 15 minutes, as of Dec 30 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

  • Revenue in USD (TTM)507.90k
  • Net income in USD-32.18m
  • Incorporated2013
  • Employees132.00
  • Location
    Co-Diagnostics Inc2401 S. Foothill Dr. Suite DSALT LAKE CITY 84109United StatesUSA
  • Phone+1 (801) 438-1036
  • Websitehttps://codiagnostics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.